Treating Corneal Thinning Conditions With CCL Vario Riboflavin (CXL) — CXL  

Keratoconus, Unstable Clinical Trial

Official title: Safety and Effectiveness of the CCL Vario System for Corneal Collagen Cross-Linking in Eyes With Corneal Thinning Conditions

Status Not yet recruiting

Clinical Trial Summary

Study is testing the efficacy of treating corneal thinning conditions with Vitamin B2 (Riboflavin) and the application on UV Light.

Clinical Trial Description

Corneal thinning conditions, i.e. keratoconus or ectasia, weaken the cornea which then causes the front of the eye to bulge out. This results in distorted vision and could eventually result in the need for a cornea transplant. This study proposes to conclude that saturating the cornea with vitamin B2 (Riboflavin) and then applying 365nm wavelength of Ultra Violet Light will result in the various layers of corneal tissue linking together. This cross linking results in a stronger cornea which is designed to halt the progression of keratoconus or ectasia. This treatment is already being successfully used in Europe. ;

Related Conditions & MeSH terms

• Keratoconus
• Keratoconus, Unstable

• NCT number: NCT04731727
• Study type: Interventional
• Source: Wellish Vision Institute
• Contact: Tony F Sterrett
• Phone: 702-932-4265
• Email: tsterrett@wellish.com
• Status: Not yet recruiting
• Phase: Early Phase 1
• Start date: June 30, 2021
• Completion date: December 2026